Skip to main
RNXT

RenovoRx (RNXT) Stock Forecast & Price Target

RenovoRx (RNXT) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

RenovoRx is a clinical-stage biopharmaceutical company with impressive pipeline and commercial potential. With the appointment of a new CFO and strong progress in clinical development, the company is well positioned for future success. Additionally, their patented Trans-Arterial Micro-Perfusion therapy platform and increased number of active commercial cancer centers show great potential for revenue growth. The company's current valuation, including cash and no debt, is attractive and projections for 2026 and 2027 show significant revenue increases.

Bears say

RenovoRx is highly dependent on the success of its proprietary Trans-Arterial Micro-Perfusion therapy platform, and potential failure to demonstrate safety and efficacy in clinical trials could lead to significant setbacks. With its relatively long induction phase for the TIGeR-PaC study and slow enrollment progress, there is a risk that the study may not be completed in a timely manner, delaying potential approval and commercialization. Additionally, there are risks associated with gaining regulatory approvals, obtaining suitable reimbursement, and competition in the biopharmaceutical industry. These factors, along with the currently negative investor sentiment towards biotech stocks, contribute to our overall negative outlook on RenovoRx's stock.

RenovoRx (RNXT) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RenovoRx (RNXT) Forecast

Analysts have given RenovoRx (RNXT) a Strong Buy based on their latest research and market trends.

According to 2 analysts, RenovoRx (RNXT) has a Strong Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RenovoRx (RNXT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.